Posted on 2/25/20
Insmed Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results . . .
Posted on 2/25/20
Antares Pharma to Report Fourth Quarter and Full Year 2019 Financial and Operating Results
EWING, N.J., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its fourth quarter and full year 2019 financial . . .
Posted on 2/24/20
Outlook Therapeutics Announces $10.2M Financings Priced At-The-Market
CRANBURY, N.J., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage?biopharmaceutical company?working to develop the first FDA-approved ophthalmic formulation of bevacizumab?for . . .
Posted on 2/24/20
A Big Month Ahead for the FDA and Bristol-Myers Squibb
It's been a few months since Bristol-Myers Squibb (NYSE:BMY) completed its $74 billion purchase of Celgene, but investors still aren't sure if a couple of key . . .
Posted on 2/24/20
Is Merck a Better Buy After Announcing Spinoff?
When companies focus on their strengths and core competencies, it can make them better investments. That's what Merck (NYSE:MRK) is hoping will happen, as the company . . .
Posted on 2/24/20
Akari Therapeutics Announces Private Placement
NEW YORK and LONDON, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune . . .
Posted on 2/24/20
BioXcel Therapeutics Prices Public Offering of Common Stock
NEW HAVEN, Conn., Feb. 20, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company, today announced the pricing of an underwritten . . .
Posted on 2/24/20
Agile Therapeutics Prices $45M Underwritten Public Offering of Common Stock
PRINCETON, N.J., Feb. 21, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the pricing of its underwritten public offering . . .
Posted on 2/21/20
Merck's Chief Digital Officer Leaves to Join Marriott
One of Merck's (NYSE:MRK) top executives has left the company and the big pharma sector, in general, to work elsewhere. Jim Scholefield, Merck's chief digital officer, . . .
Posted on 2/20/20
Is Merck & Co. Stock a Buy?
Over the past five years, shares of Merck & Co. (NYSE:MRK) are up by about 40.5%. While that isn't a bad performance, it trails that of . . .
Posted on 2/20/20
FDA Rejects New Dosing for Merck's Cancer Drug Keytruda
Merck (NYSE:MRK) on Tuesday received a complete response letter (CRL) from the Food and Drug Administration for a new dosing regimen for its cancer blockbuster Keytruda. . . .
Posted on 2/19/20
VSS Announces Investment in Ascent Behavioral Health
Investment Provides Capital to Support Next Phase of Growth for Adolescent Behavioral Health Services ProviderVeronis Suhler Stevenson, a private investment firm investing in the healthcare, information, . . .
Posted on 2/19/20
Johnson & Johnson Expands Pact With U.S. Government to Seek a Treatment for COVID-19
Johnson & Johnson (NYSE:JNJ) and the federal government are expanding their research partnership relating to COVID-19. The Biomedical Advanced Research and Development Authority (BARDA) was already . . .
Posted on 2/19/20
Pfizer Gains European Approval for Amyloidosis Drug Vyndaqel
The European Commission has officially approved Pfizer's (NYSE:PFE) drug Vyndaqel as a treatment for transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM), a disease characterized by . . .
Posted on 2/19/20
Northwell Named to Fortune’s “100 Best Companies to Work For”
NEW HYDE PARK, N.Y.--(BUSINESS WIRE)--Northwell Health has been named to Fortune’s “100 Best Companies to Work For,” the only New York health care provider to be . . .
Posted on 2/19/20
Affinity Dental Management Expands Footprint Into Metro New York
Affinity Dental Management, Inc., a dental services organization that provides comprehensive management and administrative support services for dental practices, has added the powerhouse dental practice, Concerned . . .
Posted on 2/18/20
PTC Therapeutics Launches Sixth Annual STRIVE Awards Program for Advocacy Organizations in Duchenne Muscular Dystrophy
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the sixth annual STRIVE grant awards program for Duchenne muscular dystrophy. The STRIVE Awards provide a . . .
Posted on 2/18/20
Better Buy: Biogen vs. Bristol-Myers Squibb
You don't have to look back too far to find a time when Biogen (NASDAQ:BIIB) and Bristol-Myers Squibb (NYSE:BMY) claimed very similar market caps. That was . . .
Posted on 2/18/20
Merck's Ebola Vaccine Approved for Use in Four African Countries
Merck (NYSE:MRK) announced on Friday that four African countries had approved the use of the company's Ebola vaccine, Ervebo. The Democratic Republic of the Congo (DRC), . . .
Posted on 2/18/20
Outlook Therapeutics Provides Business Update
CRANBURY, N.J., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a?late clinical-stage?biopharmaceutical company?working to develop the first FDA-approved ophthalmic formulation of bevacizumab?for use . . .
Posted on 2/18/20
The Benchmark Company Closes Public Offering of $5m for Seelos Therapeutics
NEW YORK, Feb. 13, 2020 (GLOBE NEWSWIRE) -- The Benchmark Company today announced the closing of an Underwritten Public Offering for Seelos Therapeutics, Inc. of 6,666,667 . . .
Posted on 2/18/20
Seelos Therapeutics Closes Public Offering of Common Stock
NEW YORK, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous . . .
Posted on 2/14/20
FDA Gives Bristol-Myers Squibb's CAR-T Liso-Cel a Priority Review
The Food and Drug Administration is giving a priority review to lisocabtagene maraleucel (liso-cel), a CAR-T (chimeric antigen receptor T-cell) therapy from Bristol-Myers Squibb (NYSE:BMY). The . . .
Posted on 2/14/20
Merck Spins, And Falls: Why I Am More Bullish Than The Street
SummaryMRK has gone into a tailspin since its Q4 conference call.It reported a fair but not great Q4, and surprised and disappointed the Street with a . . .
Posted on 2/14/20
Zoetis Reports Q4 Financial Results, Slightly Beats Revenue Estimates
Zoetis (NYSE:ZTS), the animal-health company, reported fiscal fourth-quarter and 2019 full-year financial results Thursday morning. Revenue slightly beat analyst expectations.Quarterly revenue came in at $1.7 billion, . . .
New York
